Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. (NASDAQ: ALBT) generates news across precision diagnostics, cellular therapy intellectual property, generative AI software, and commercial real estate. Company press releases describe Avalon as a commercial‑stage developer of precision diagnostic consumer products, with a flagship focus on the KetoAir™ handheld breathalyzer for ketogenic health management. News coverage frequently highlights deployments of KetoAir™ in wellness initiatives, first responder programs, and international online sales channels.
Investors following ALBT news will see updates on distribution agreements, affiliate marketing programs, and partnerships that incorporate KetoAir™ as a real‑time metabolic monitoring tool. Recent announcements include collaborations with Saga Health Corporation and SpecialtyHealth, Inc. for first responder wellness programs, as well as expansion of KetoAir™ availability into the United Kingdom through online sales. Avalon also reports on its co‑development agreement with Qi Diagnostics Limited to create a VOC nanosensor‑based cannabis breathalyzer aimed at supporting detection of potential cannabis‑impaired driving.
Beyond diagnostics, Avalon’s news flow includes developments in its cellular therapy intellectual property portfolio, such as the issuance of a Hong Kong patent for proprietary CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited. The company also issues updates on its acquisition of RPM Interactive, Inc. and the Catch‑Up generative AI SaaS platform, which is designed to automate short‑form video creation and support marketing for KetoAir™ and other consumer health products.
Regulatory and corporate actions also feature in ALBT news, including SEC filings, financing transactions, Nasdaq listing compliance updates, and progress on the proposed merger with YOOV Group Holding Limited. Readers can use this news stream to monitor how Avalon’s precision diagnostics, AI‑driven software, cellular therapy IP, and capital markets activities evolve over time.
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the launch of a direct-to-consumer DNA test for opioid addiction predisposition through its 40% owned Laboratory Services MSO. The DNA4Addiction test analyzes 15 genetic markers linked to opioid dependence, categorizing individuals into risk levels. This non-invasive, at-home test comes amid the ongoing opioid crisis, with opioids involved in over 75% of nearly 107,000 drug overdose deaths in 2022.
The test aims to provide insights for proactive health management, though it is not a diagnosis. It examines factors such as neurotransmitter activity and substance sensitivity. Dr. David Jin, CEO of Avalon, emphasized the importance of recognizing genetic predisposition for early intervention. Bob Forrest, Brand Ambassador for DNA4Addiction, highlighted its potential in guiding lifestyle changes and preventing addiction, especially for parents concerned about their children's risks.
Avalon GloboCare Corp. (NASDAQ: ALBT) has launched online sales of the KetoAir™ breathalyzer in the U.S. at www.ketoair.us. This FDA-registered device features Hot App shareable technology with AI-enabled software for ketogenic health management. The KetoAir™ breathalyzer uses nano-sensor-based technology and AI algorithms to assess ketosis status and record diet and exercise details via its app.
The device offers personalized nutritional and exercise recommendations through its AI nutritionist feature. Avalon has exclusive distributorship rights for KetoAir™ in North America, South America, EU, and the UK. To celebrate the launch, Avalon is offering a special introductory price of $199 (regular $249) with an additional 20% discount using coupon code 'intro20'.
Avalon GloboCare announced the successful U.S. launch of its KetoAir™ breathalyzer at the Hack Your Health by KetoCon 2024 Conference. The event, held from May 31 to June 2, 2024, in Austin, Texas, attracted diverse stakeholders such as doctors, health coaches, and retailers. The device, registered with the FDA (No. 3026284320), uses AI-enabled software and nano-sensor technology to monitor ketosis through a non-invasive breath test. Avalon introduced a Zero to Keto program and expects retail sales to begin later this month, with purchases available exclusively at KetoAir.com.
Avalon GloboCare (NASDAQ: ALBT) announced that it has received a notice from Nasdaq on May 22, 2024, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.
The notice does not affect the immediate listing or trading of Avalon's common stock. The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may allow until November 18, 2024, for Avalon to file the report and regain compliance. Avalon is working to finalize and file the report promptly.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.